Top entities: Disc Medicine, Rosen Law Firm, United States — Food and Drug Administration, Philip Kim, Lawrence Rosen.

What category does this event fall under?

Regulatory — classified as securities litigation.

What is the sentiment of coverage?

Aggregate sentiment score: -20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated May 12, 2026. Coverage continues to evolve.

Regulatory securities litigation

Disc Medicine FDA Rejection, Lawsuit

Q: When did this event occur?

First reported May 01, 2026; last updated May 12, 2026.

Q: What is the market impact?

Direct. The market is impacted by the potential for a class action lawsuit against Disc Medicine, Inc.

Q: What were the key actions taken?

Disc Medicine stock price fell · United States — Food and Drug Administration issued Complete Response Letter Disc Medicine · Rosen Law Firm investigates securities claims Disc Medicine

Analysis based on 7 articles · First reported May 01, 2026 · Last updated May 12, 2026

Sentiment

-20

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The market is impacted by the potential for a class action lawsuit against Disc Medicine, Inc., which could lead to financial penalties and further stock price depreciation. Investors in Disc Medicine, Inc. are facing losses due to the United States — Food and Drug Administration's decision.

Biotechnology Legal Services

Event Summary

Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. following a significant drop in its stock price. This decline occurred on February 13, 2026, after the United States — Food and Drug Administration issued a Complete Response Letter for Disc Medicine, Inc.'s bitopertin program, indicating that the new drug application could not be approved due to uncertainties requiring additional evidence. Rosen Law Firm is preparing a class action lawsuit to recover investor losses, alleging that Disc Medicine, Inc. may have issued materially misleading business information to the investing public. Philip Kim and Lawrence Rosen are key contacts for investors interested in joining the prospective class action.

Key Actions

95 Disc Medicine stock price fell

90 United States — Food and Drug Administration issued Complete Response Letter Disc Medicine

80 Rosen Law Firm investigates securities claims Disc Medicine

Entities Involved

stock

Disc Medicine

Disc Medicine, Inc. received a Complete Response Letter from the United States — Food and Drug Administration regarding its bitopertin program, leading to a 22% stock price drop and subsequent securities claims investigation.

Importance 100 Sentiment -50

priv

Rosen Law Firm

Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. and is preparing a class action lawsuit on behalf of investors.

Importance 80 Sentiment 20

govactor

United States — Food and Drug Administration

The United States — Food and Drug Administration issued a Complete Response Letter to Disc Medicine, Inc. for its bitopertin program, citing uncertainties in the new drug application.

Importance 70 Sentiment 0

per

Philip Kim

Philip Kim is an attorney at Rosen Law Firm and is listed as a contact for investors interested in joining the class action against Disc Medicine, Inc.

Importance 30 Sentiment 0

per

Lawrence Rosen

Lawrence Rosen is a founding partner of Rosen Law Firm, which is investigating Disc Medicine, Inc. for securities claims.

Importance 30 Sentiment 0

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard